Keywords: 18f-Fdg Pet Ct, 99mtc-Mibi, Multiple Myeloma, Prognosis, Fluorodeoxyglucose F 18, Methoxy Isobutyl Isonitrile Technetium Tc 99m, Article, Cancer Growth, Cancer Patient, Cancer Regression, Cancer Survival, Clinical Article, Female, Follow Up, Human, Intermethod Comparison, Outcome Assessment, Overall Survival, Pet-Ct Scanner, Progression Free Survival, Whole Body Ct, Whole Body Mri, Whole Body Pet, Whole Body Scanner, Radiopharmaceutical Agent, Adult, Comparative Study, Computer Assisted Tomography, Diagnostic Use, Middle Aged, Multimodal Imaging, Nuclear Magnetic Resonance Imaging, Positron Emission Tomography, Predictive Value, Scintiscanning, Very Elderly, 80 And Over, Positron-Emission Tomography, Predictive Value Of Tests, Survival Analysis, Technetium Tc 99m Sestamibi, X-Ray Computed,
Affiliations: *** IBB - CNR ***
From the *Institute of Biostructures and Bioimages, National Research Council, Naples
†Department of Medicine and Surgery, University of Salerno, Salerno
Departments of ‡Hematology, and §Advanced Biomedical Sciences, University of Federico II, Naples, Italy.
daggerDepartment of Medicine and Surgery, University of Salerno, Salerno
Departments of double daggerHematology, and section signAdvanced Biomedical Sciences, University of Federico II, Naples, Italy.
Department of Hematology, University of Federico II, Naples, Italy
Department of Advanced Biomedical Sciences, University of Federico II, Naples, Italy
IBB-CNR, Università di Salerno, Università Federico II di Napoli, Università Federico II di Napoli, IBB-CNR, Università Federico II di Napoli, Università Federico II di Napoli, IRCCS-SDN, Università Federico II di Napoli.
References: Bodet-Milin, C., Eugène, T., Bailly, C., FDG-PET in the evaluation of myeloma in 2012 (2013) Diagn Interv Imaging, 94, pp. 184-18
Munshi, N.C., Anderson, K.C., Bergsagel, P.L., Consensus recommendations for risk stratification in multiple myeloma: Report of the International Myeloma Workshop Consensus Panel 2 (2011) Blood, 117, pp. 4696-4700
Bird, J.M., Owen, R.G., D'Sa, S., Guidelines on the diagnosis and management of multiple myeloma 2011 (2011) Br J Haematol, 154, pp. 32-75
San-Miguel, J.F., Paiva, B., Gutiérrez, N.C., New tools for diagnosis and monitoring of multiple myeloma (2013) Am Soc Clin Oncol Educ Book, 1, pp. 313-1138
Kyle, R.A., Rajkumar, S.V., Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma (2009) Leukemia, 23, pp. 3-9
Durie, B.G., Salmon, S.E., A clinical staging system for multiple myeloma. Correlation of measured myeloma cells mass with presenting clinical features, response to treatment and survival (1975) Cancer, 36, pp. 842-854
Durie, B.G., Kyle, R.A., Belch, A., Myeloma management guidelines: A consensus report from the Scientific Advisors of the International Myeloma Foundation (2003) Hematol J, 4, pp. 379-398
Durie, B.G., The role of anatomic and functional staging in myeloma: Description of Durie/Salmon plus staging system (2006) Eur J Cancer, 42, pp. 1539-1543
Zamagni, E., Cavo, M., The role of imaging techniques in the management of multiple myeloma (2012) Br J Haematol, 159, pp. 499-513
Pace, L., Catalano, L., Pinto, A., Different patterns of technetium-99m sestamibi uptake in multiple myeloma (1998) Eur J Nucl Med, 25, pp. 714-720
Mele, A., Offidani, M., Visani, G., Technetium-99m sestamibi scintigraphy is sensitive and specific for the staging and the follow-up of patients with multiple myeloma: A multicentre study on 397 scans (2007) Br J Haematol, 136, pp. 729-735
Catalano, L., Pace, L., Califano, C., Detection of focal myeloma lesions by technetium-99m-sestaMIBI scintigraphy (1999) Haematologica, 84, pp. 119-124
Mileshkin, L., Blum, R., Seymour, J.F., A comparison of fluorine-18 fluorodeoxyglucose PET and technetium-99m sestamibi in assessing patients with multiple myeloma (2004) Eur J Haematol, 72, pp. 32-37
Andretta, C., Catalano, L., Pace, L., 99mTc-sestamibi scintigraphy in thalidomide-treated refractory or relapsed multiple myeloma patients (2003) Leuk Lymphoma, 44, pp. 1081-1082
Hung, G.U., Tsai, C.C., Tsai, S.C., Comparison of Tc-99m sestamibi and F-18 FDG-PET in the assessment of multiple myeloma (2005) Anticancer Res, 25, pp. 4737-4741
Catalano, L., Del Vecchio, S., Petruzziello, F., Sestamibi and FDG-PET scans to support diagnosis of jaw osteonecrosis (2007) Ann Hematol, 86, pp. 415-423
Fonti, R., Del Vecchio, S., Zannetti, A., Bone marrow uptake of 99mTc-MIBI in patients with multiple myeloma (2001) Eur J Nucl Med, 28, pp. 214-220
Bacovsky, J., Myslivecek, M., Scudla, V., Tc-99m MIBI scintigraphy inmultiple myeloma: Prognostic value of different Tc-99m MIBI uptake patterns (2010) Clin Nucl Med, 35, pp. 667-670
Martin, M.G., Romero Colas, M.S., Dourdil Sahun, M.V., Baseline Tc99-MIBI scanning predicts survival in multiple myeloma and helps to differentiate this disease from monoclonal gammopathy of unknown significance (2005) Haematologica, 90, pp. 1141-1143
Fonti, R., Salvatore, B., Quarantelli, M., 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma (2008) J Nucl Med, 49, pp. 195-200
Moulopoulos, L.A., Dimopoulos, M.A., Magnetic resonance imaging of the bone marrow in hematologic malignancies (1997) Blood, 90, pp. 2127-2147
Koppula, B., Kaptuch, J., Hanrahan, C.J., Imaging of multiple myeloma: Usefulness of MRI and PET/CT (2013) Semin Ultrasound CT MR, 34, pp. 566-577
Regelink, J.C., Minnema, M.C., Terpos, E., Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: A systematic review (2013) Br J Haematol, 162, pp. 50-61
Walker, R.C., Brown, T.L., Jones-Jackson, L.B., Imaging of multiple myeloma and related plasma cell dyscrasias (2012) J Nucl Med, 53, pp. 1091-1101
Tan, E., Weiss, B.M., Mena, E., Current and future imaging modalities for multiple myeloma and its precursor states (2011) Leuk Lymphoma, 52, pp. 1630-1640
Bartel, T.B., Haessler, J., Brown, T.L., F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma (2009) Blood, 114, pp. 2068-2076
Fonti, R., Larobina, M., Del Vecchio, S., Metabolic tumor volume assessed by 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma (2012) J Nucl Med, 53, pp. 1829-1835
Walker, R., Barlogie, B., Haessler, J., Magnetic resonance imaging in multiple myeloma: Diagnostic and clinical implications (2007) J Clin Oncol, 25, pp. 1121-1128
Nanni, C., Zamagni, E., Farsad, M., Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: Preliminary results (2006) Eur J Nucl Med Mol Imaging, 33, pp. 525-531
Bataille, R., Annweiler, C., Beauchet, O., Multiple myeloma international staging system: "Staging" or simply "aging" system? (2013) Clin Lymphoma Myeloma Leuk, 13, pp. 635-637
Avet-Loiseau, H., Role of genetics in prognostication in myeloma (2007) Best Pract Res Clin Haematol, 20, pp. 625-635
Nahi, H., Sutlu, T., Jansson, M., Clinical impact of chromosomal aberrations in multiple myeolma (2011) J Intern Med, 269, pp. 137-147
An, G., Xu, Y., Shi, L., t(11-14) multiple myeloma: A subtype associated with distinct immunological features, immunophenotypic characteristics but divergent outcome (2013) Leuk Res, 37, pp. 1251-1257
18F-FDG PET/CT, 99mTc-MIBI, and MRI in the prediction of outcome of patients with multiple myeloma: a comparative study
Hesse B, Tagil K, Cuocolo A, Anagnostopoulos C, Bardies M, Bax J, Bengel F, Busemann Sokole E, Davies G, Dondi M, Edenbrandt L, Franken P, Kjaer A, Knuuti J, Lassmann M, Ljungberg M, Marcassa C, Marie PY, Mckiddie F, O'connor M, Prvuolovich E, Underwood R * 3. 0 T perfusion MR imaging(694 views) Rivista Di Neuroradiologia (ISSN: 1120-9976), 2004; 17(6): 807-812. Impact Factor:0.023 ViewExport to BibTeXExport to EndNote